Adverse events after Fluzone® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013

Vaccine

Volumn 31, Issue 43, 2013, Pages 4984-4987

  Moro, Pedro L ^a   Harrington, Theresa ^a   Shimabukuro, Tom ^a   Cano, Maria ^a   Museru, Oidda I ^a   Menschik, David ^b   Broder, Karen ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Adverse event; Intradermal; Surveillance; Trivalent inactivated influenza vaccine; Vaccine safety

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ALLERGY; ANAPHYLAXIS; ARTICLE; BELL PALSY; CHILD; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DIGESTIVE SYSTEM DISEASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FATALITY; HEART DISEASE; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE NODULE; INJECTION SITE PRURITUS; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MEDICAL RECORD; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SEIZURE; SIDE EFFECT;

ADVERSE EVENT; INTRADERMAL; SURVEILLANCE; TRIVALENT INACTIVATED INFLUENZA VACCINE; VACCINE SAFETY;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84885185811     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.001     Document Type: Article

References (23)

1. Food and Drug Administration May 9, 2011 Approval Letter - Fluzone Intradermal. Available at: [accessed 09.01.12]. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm255160.htm.
2. Centers for Disease Control and Prevention (CDC) Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011, 60(August (33)):1128-1132.
3. Centers for Disease Control and Prevention (CDC) Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2012-13 Influenza Season. MMWR Morb Mortal Wkly Rep 2012, 61(August (32)):613-618.
4. Hickling J.K., Jones K.R., Friede M., Zehrung D., Chen D., Kristensen D. Intradermal delivery of vaccines: potential benefits and current challenges. Bull World Health Organ 2011, 89(3):221-226.
5. Food and Drug Administration, Fluzone, Fluzone High-Dose and Fluzone Intradermal. [accessed 28.03.13]. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM305080.pdf.
6. ®) administered by intradermal and intramuscular route in healthy adults. Vaccine 2011, 29:5666-5674.
7. Leroux-Roels I., Vets E., Freese R., Seiberling M., Weber F., Salamand C., et al. Seasonal influenza vaccine delivered by intradermal microinjection: a randomized controlled safety and immunogenicity trial in adults. Vaccine 2008, 26:6614-6619.
8. European Medicines Agency. Intanza® influenza vaccine (split virion, inactivated). [accessed 19.07.13]. http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/medicines/000957/human_med_000842.jsp%26murl=menus/medicines/medicines.jsp%26mid=WC0b01ac058001d124.
9. Canada Communicable Disease Report. Addendum to the 2010-2011 Seasonal Trivalent Inactivated Influenza Vaccine. Recommendations on the use of intradermal trivalent inactivated influenza vaccine (TIV-ID).September 2011, vol. 37. ACS-4 [accessed 19.07.13]. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/11vol37/acs-dcc-4/.
10. Australian Government Department of Health and Aging 2013, Australian Register of Therapeutic Goods, Intanza, htttp://search-au.funnelback.com/s/search.html?collection=tga-artg&profile=record&meta_i=170210 [accessed July 19].
11. ®: a new intradermal vaccine for seasonal influenza. Expert Rev Vaccines 2010, 9(December (12)):1399-1409. 10.1586/erv.10.134.
12. ® 9μg intradermal seasonal influenza vaccine for adults 18 to 59 years of age. Hum Vaccin Immunother 2013, 9(1):115-121. 10.4161/hv.22342.
13. Varricchio F., Iskander J., Destefano F., Ball R., Pless R., Braun M.M. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004, 23(4):287-294.
14. Medical Dictionary for Regulatory Activities. Available at: [accessed 28.04.11]. http://www.meddramsso.com/.
15. Food and Drug Administration. 21 CFR Part 600.80. Postmarketing reporting of adverse experiences. vol. 62: Federal Register; 1997:52252-52253.
16. Vellozzi C., Broder K.R., Haber P., Guh A., Nguyen M., Cano M., et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine 2010, 28:7248-7255.
17. Rüggeberg J.U., Gold M.S., Bayas J.M., Blum M.D., Bonhoeffer J., Friedlander S., et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25:5675-5684.
18. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat 1999, 53:177-190.
19. Szarfman A., Machado S.G., O'Neill R.T. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 2002, 25:381-392.
20. Martin D., Menschik D., Bryant-Genevier M., Ball R. Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine. Drug Saf 2013, 36:547-556.
21. Chapter 385. Guillain-Barré syndrome and other immune-mediated neuropathies. Chronic inflammatory demyelinating polyneuropathy. Harrison's principles of internal medicine 2012, The McGraw-Hill Companies, Inc, New York. 18th edition. L. Dan, Longo, S. Anthony, Fauci, L. Dennis, Kasper, L. Stephen, J. Hauser, Larry Jameson, Joseph Loscalzo (Eds.).
22. Institute of Medicine Influenza vaccines. Adverse effects of vaccines: evidence and causality 2011, 257-368. The National Academies Press, Washington DC.
23. Greene S.K., Kulldorff M., Lewis E.M., Li R., Yin R., Weintraub E.S., et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the vaccine safety Datalink project. Am J Epidemiol 2010, 171:177-188.